The largest database of trusted experimental protocols

Prednisone

Prednisone is a synthetic corticosteroid drug that is used to treat a wide range of inflammatory and autoimmune conditions.
It is structurally similar to the naturally occurring hormone cortisol and is commonly prescribed for its potent anti-inflammatory and immunosuppresive effects.
Prednisone can be administered orally, topically, or by injection, and its use is typically monitored closely by healthcare providers due to the potential for adverse effects.
Researchers studying the efficacy and safety of prednisone can utilize PubCompare.ai, an AI-driven platform that helps identify the most reproducible and effective prednisone products by comparing protocols from literature, preprints, and patents.
This tool can streamline research and optimize prednisone studies to improve patient outcomes.

Most cited protocols related to «Prednisone»

Data for this study were acquired from a recently completed placebo-controlled randomized trial of rosiglitazone for mild to moderately active ulcerative colitis (clinicaltrials.gov #NCT00065065) which has been described in greater detail previously.7 (link) The trial used a slight modification of the Mayo score to assess disease activity (Table 1). Specifically, the bleeding component as described in the Mayo index was modified such that a score of 3 required both visible blood in 50% or more of bowel movements and at least some bowel movements with blood alone.
The study included 105 patients with mild to moderately active disease defined as a total DAI score of 4 to 10, inclusively. Patients were randomized in a 1:1 ratio to receive either rosiglitazone 4 mg or placebo twice daily for 12 weeks. Disease activity was measured at randomization and every four weeks thereafter until week 12, however lower endoscopy was only completed at week 0 and week 12, such that only a partial Mayo score (9 point scale that excludes the endoscopic appearance of the mucosa) could be calculated at the interim visits. In the very early accrual period of the study, a follow-up visit was included at week 2. Without knowledge of the response rates in either arm, the Data and Safety Monitoring Board (DSMB) requested that the week 2 follow-up evaluation be eliminated with the hopes of minimizing the placebo response rate and maximizing recruitment and retention.6 (link), 8 (link), 9 (link) Eighteen patients completed the week 2 follow-up visit.
During the course of the study, patients could be treated with other conventional medications used to treat active ulcerative colitis including mesalamine, oral corticosteroids, immunomodulators, or topical therapies (mesalamine or corticosteroids) at stable doses. Use of corticosteroids at doses greater than 20mg per day of prednisone or the equivalent was an exclusion criterion. Steroid tapering was not permitted during the study.
In anticipation of this sub-study, at each visit we also included questions about change in disease activity compared to the previous visit and compared to the randomization visit on a global seven-point scale (Table 2). The choices included much better, moderately better, a little better, unchanged, a little worse, moderately worse, and much worse. Patients also graded their current disease activity at each visit on a 6 point Likert scale – perfect, very good (minimal symptoms), good (only mild symptoms), moderately active, moderately severe, or severe. Data on quality of life were measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) authored by Dr. Jan Irvine under license from McMaster University, Hamilton, Canada.10 (link)
Publication 2008
Adrenal Cortex Hormones BLOOD Clinical Trials Data Monitoring Committees Defecation Endoscopy Endoscopy, Gastrointestinal Immunologic Adjuvants Inflammatory Bowel Diseases Mesalamine Mucous Membrane Patients Pharmaceutical Preparations Placebos Prednisone Retention (Psychology) Rosiglitazone Steroids Ulcerative Colitis
The study was a prospective cohort study that included a cohort of patients with new-onset PMR and a comparison cohort of non-PMR patients with various conditions mimicking PMR. Study subjects were recruited from 21 community-based and academic rheumatology clinics in 10 European countries and the USA. Inclusion criteria for PMR patients were age 50 years or older, new-onset bilateral shoulder pain and no corticosteroid treatment (for any condition) within 12 weeks before study entry, fulfilling all the inclusion and exclusion criteria defined by our previous report and in accordance with the judgement of the participating investigator that the patient had PMR.18 (link) Every effort was made to choose patients across the spectrum of disease severity. Corticosteroid treatment for PMR patients was initiated according to a predefined treatment protocol starting with 15 mg a day oral prednisone for weeks 1 and 2, 12.5 mg a day for weeks 3 and 4, 10 mg a day for weeks 6–11, 10 mg/7.5 mg every other day for weeks 12–15, 7.5 mg a day for weeks 16–25 and tapering according to treatment response from week 26 onwards. The gold standard for the pre-steroid diagnosis of PMR was established as above at presentation and when the diagnosis was maintained without an alternative diagnosis at week 26 of follow-up.
The non-PMR comparison cohort included conditions representative of the types that need to be distinguished from PMR, in both primary and secondary care. Inclusion criteria for the non-PMR comparison cohort were age 50 years or older, new-onset bilateral shoulder pain and a diagnosis of either inflammatory or non-inflammatory conditions, including new-onset RA, connective tissue diseases, various shoulder conditions (eg, bilateral rotator cuff syndrome and/or adhesive capsulitis, rotator cuff tear, glenohumeral osteoarthritis), fibromyalgia, generalised osteoarthritis and others. Patients known to have the condition for more than 12 weeks before the baseline evaluation (except fibromyalgia and chronic pain) were not eligible for inclusion. PMR patients with clinical suspicion of giant cell arteritis were included as part of the comparison cohort because these patients required different corticosteroid doses. Patients in the comparison cohort were included on the basis of clinician diagnosis and not on formal criteria. No guidelines were provided for treatment of the conditions in the comparison cohort.
Ethics board approval was obtained at all participating institutions before initiation of the study, and all participants gave written informed consent before enrollment.
Publication 2012
Adhesive Capsulitis Adrenal Cortex Hormones Chronic Pain Connective Tissue Diseases Degenerative Arthritides Diagnosis Europeans Fibromyalgia Giant Cell Arteritis Gold Inflammation Patients Prednisone Rotator Cuff Secondary Care Shoulder Shoulder Pain Steroids Syndrome Treatment Protocols
In this phase 3, multicenter, randomized, double-blind, placebo-controlled trial, patients with SLE on SOC therapy were assigned to receive placebo, or belimumab 1 or 10 mg/kg by intravenous (IV) infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 72. While the initiation of an immunosuppressive (IS) drug was prohibited during the trial, the addition of a new antimalarial (AM) drug and dose increases of concomitant IS or AM drugs were permitted until week 16. After week 16, however, the maximum doses of IS or AM drugs could be no greater than the higher of the baseline or week-16 dose. For corticosteroids, any dose was permitted through week 24; thereafter through week 44, the dose had to be within 25% or 5 mg of baseline. Between weeks 44 and 52, no increase over the higher of the baseline or week-44 dose was permitted. From weeks 52 through 68, the dose had to be within 25% or 5 mg of baseline, and an increase over the higher of the baseline or week-68 dose was prohibited after week 68. Prednisone could be reduced at the discretion of the investigator. As in the companion phase 3 BLISS-52 trial, the addition of a new biologic agent at any time, an inhibitor of the renin-angiotensin system after 4 months, or a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor after 6 months was prohibited; other antihypertensive or lipid-lowering agents were allowed during the study (17 (link)). The Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index (SELENA-SLEDAI) (18 (link)), Physician’s Global Assessment (PGA) (18 (link)), British Isles Lupus Assessment Group (BILAG) (19 (link),20 (link)), and SLE Flare Index (SFI) (21 (link)) were evaluated every 4 weeks (except weeks 56 and 64), as were AEs, vital signs, concomitant medications, and laboratory and pregnancy tests.
Publication 2011
Adrenal Cortex Hormones Angiotensins Antihypertensive Agents Antimalarials belimumab Biological Factors Coenzyme A Estrogens Hypolipidemic Agents Immunosuppressive Agents Intravenous Infusion Lupus Vulgaris Oxidoreductase Patients Pets Pharmaceutical Preparations Physicians Placebos Prednisone Pregnancy Tests Renin Inhibitors Safety Signs, Vital Therapeutics
Patients who consented to the optional therapeutic window were randomized to receive upfront methotrexate over 4 or 24 hours. Four days after methotrexate treatment, remission induction therapy began with prednisone, vincristine, daunorubicin, and asparaginase (Table 1). Patients with ≥ 1% MRD on day 19 received three additional doses of asparaginase. Subsequent induction therapy consisted of cyclophosphamide, mercaptopurine and cytarabine. Upon hematopoietic recovery (between days 43 and 46), MRD was assessed, and consolidation therapy began (Table 1).
Publication 2009
Asparaginase Cyclophosphamide Cytarabine Daunorubicin Hematopoietic System Mercaptopurine Methotrexate Neoadjuvant Therapy Patients Prednisone Remission Induction Therapeutics Vincristine
The Health Sciences Research Ethics Board at the University of Western Ontario granted ethical approval for the study under approval number REB16183E. Participants gave their signed informed consent before the start of the study. Premenopausal women between the ages of 18-40 years were recruited at the Victoria Family Medical Center in London, Canada. Participants were excluded from the study if they reached menopause, were menstruating, had a urogenital infection other than BV in the past 6 months, were pregnant, had a history of gonorrhoea, chlamydia, estrogen-dependent neoplasia, abnormal renal function or pyelonephritis, were taking prednisone, immunosuppresives or antimicrobial medication, had undiagnosed abnormal vaginal bleeding, had engaged in oral or vaginal intercourse or consumed probiotic ements or foods in the 48 hours prior to the clinical visit.
Full text: Click here
Publication 2013
Chlamydia Coitus Estrogens Food Gonorrhea Infection Kidney Menopause Microbicides Neoplasms Pharmaceutical Preparations Prednisone Probiotics Pyelonephritis System, Genitourinary Woman

Most recents protocols related to «Prednisone»

Example 7

A patient with multiple myeloma is treated with BiCNU® (carmustine for injection), a nitrosourea (1,3-bis(2-chloroethyl)-1-nitrosourea) in combination with prednisone. The dose of BiCNU administered to this previously untreated patient is 200 mg/m2 intravenously every 6 weeks. This is divided into daily injections of 100 mg/m2 on 2 successive days. DDFPe is administered as an IV bolus (dose=0.2 cc/kg, 2% w/vol DDFP) during each dose of BiCNU while the patient breathes supplemental oxygen for 60 minutes. A repeat course of BiCNU is again administered once the circulating blood elements have returned to acceptable levels (platelets above 100,000/mm3, leukocytes above 4,000/mm3), in 6 weeks, and again DDFPe is administered concomitantly with BiCNU.

Full text: Click here
Patent 2024
BiCNU Blood Component Transfusion Blood Platelets Carmustine Leukocytes Multiple Myeloma Nitrosourea Compounds Oxygen Patients Pharmacotherapy Prednisone Radiotherapy Therapeutics
Medication endpoints were the dispensation of infliximab, including initial and subsequent dispensations, infliximab dose escalation (defined as a 25% or greater increase in daily dose for the current prescription compared with the average of earlier dispensations), the dispensation of a different biologic medication, the dispensation of antibiotic medication used for IBD-related conditions, and new use of prednisone, defined as the absence of days supply of any systemic corticosteroid in the 6 months prior to the dispensing of prednisone. Supplementary Table 3 lists the medications monitored. For the policy cohort only, we also measured switching to biosimilar infliximab separately for adult and pediatric patients with IBDs. Health services endpoints were outpatient visits to a physician (any specialty) or nurse practitioner, outpatient visits to a gastroenterologist, visits to an emergency department, discharges from a hospital, and emergency admissions to a hospital.
Full text: Click here
Publication 2023
Adrenal Cortex Hormones Adult Antibiotics Biopharmaceuticals Biosimilars Emergencies Gastroenterologist Infliximab Outpatients Patients Pharmaceutical Preparations Physicians Practitioner, Nurse Prednisone
A 35-year-old incarcerated AA male was admitted to the hospital several times for hematochezia with multiple unrevealing endoscopic evaluations. He was readmitted for a gastroenterology (GI) bleed, and magnetic resonance enterography (MRE) and fecal calprotectin were again unremarkable. Repeat colonoscopy showed severe inflammation of the terminal ileum (TI) with patchy mild–moderate inflammation of colon and pathology consistent with idiopathic IBD. He was started on IV steroids and discharged on an oral prednisone taper for 9 weeks. Initial planned outpatient therapy was 5 mg/kg infliximab, but he experienced a delayed start requiring an additional steroid taper. Infliximab was started 4 months later at standard dosing. He unfortunately was late for his second dose and missed his third dose due to hospitalization for ongoing symptoms. During that admission, his anemia was so severe that a blood transfusion was required. At that time, the decision was made to reinduce with an increased dose at 10 mg/kg every 4 weeks with the first dose on the day of discharge. Since that time, he has been late for multiple infusions due to prison-related scheduling issues. After requiring his fifth prolonged prednisone taper in 1 year, he underwent infliximab reload at 10 mg/kg. He again was late for his every 4-week maintenance infusions. Since being released from prison, he has been on time for infliximab infusions 10 mg/kg every 8 weeks with reported improvement in his diarrhea and hematochezia. Subsequent endoscopy revealed resolution of the TI disease with patchy mild colitis in only 1 region of the colon. His dosing regimen was optimized to 10 mg/kg every 4 weeks and clinically he has been doing well.
Full text: Click here
Publication 2023
Anemia Blood Transfusion Colitis Colon Colonoscopy Diarrhea Endoscopy Feces Granulomatous Colitis Hematochezia Hospitalization Ileal Diseases Ileitis Infliximab Leukocyte L1 Antigen Complex Magnetic Resonance Imaging Males Outpatients Prednisone Steroids Therapeutics Treatment Protocols
This exploratory, prospective, single-centre, longitudinal, observational study will be enrolling patients with clinically stable COPD who are referred to an 8-week inpatient pulmonary rehabilitation (PR) programme at Ciro. Clinical stability will be defined by haemodynamic and respiratory stability, without initiation of antibiotics or prednisone treatment ≤7 days prior to study entry. The expected study duration is 1.5 years from enrolment of the first patient (July 2022) to the last patient (January 2024). To explore early AECOPD biomarkers, a panel of prespecified biomarkers will be assessed on a daily or three times weekly basis, with additional measurements during AECOPD and at outcome assessment (figure 1).
Publication 2023
Antibiotics, Antitubercular Biological Markers Chronic Obstructive Airway Disease Hemodynamics Inpatient Lung Patients Prednisone Rehabilitation Respiratory Rate
We analyzed patients with acute or lymphoma-type ATLL who were diagnosed at our hospital between 2014 and 2020 and underwent initial treatment with a CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-based chemotherapy regimen. Patients who received mogamulizumab in combination with CHOP therapy were also included in this analysis. Patients with any of the following histories were excluded: 1) receiving any anti-cancer drugs, immunosuppressants, or radiation therapy within the last five years; and 2) having any serious infectious diseases within the past 12 months. We also excluded patients with iron or vitamin deficiencies at the time of initial diagnosis. To minimize the effect of anticancer drugs on hematopoiesis and RBC morphology, peripheral blood smears and laboratory data were collected within two weeks of treatment intervention. Based on past clinical observations, these two weeks was the time when the actual major changes in RBC morphology have been observed. Blood smears were collected exclusively from the patients with acute-type ATLL who were available for the appraisable peripheral blood smears and were evaluated by a physician and authorized laboratory technologists. Data on the peripheral blood cell count, mean corpuscular volume (MCV), red cell distribution width (RDW), hemoglobin (Hb), lactate dehydrogenase (LDH), and soluble interleukin-2 receptor (sIL-2R) were collected, and the trends of these data over time were examined. To examine the factors influencing the progression of anemia, the association between the degree of progression of anemia and LDH, sIL2R, and RDW was statistically analyzed. Statistical analyses were conducted using the Shapiro test and cor test functions of R version 4.2.0.
Full text: Click here
Publication 2023
Anemia Antineoplastic Agents BLOOD Blood Cell Count Communicable Diseases Cyclophosphamide DDIT3 protein, human Diagnosis Disease Progression Doxorubicin Erythrocyte Volume, Mean Cell Hematopoiesis Hemoglobin Immunosuppressive Agents Interleukin 2 Receptor Iron Lactate Dehydrogenase Lymphoma mogamulizumab Patients Pharmacotherapy Physicians Prednisone Radiotherapy Red Cell Distribution Width T-Cell Leukemia-Lymphomas, Adult Treatment Protocols Vincristine Vitamin Deficiency

Top products related to «Prednisone»

Sourced in United States, Italy, Germany, France, China
Prednisone is a synthetic corticosteroid medication used in the treatment of various medical conditions. It is a pharmaceutical product developed by Merck Group for therapeutic purposes. The core function of Prednisone is to provide anti-inflammatory and immunosuppressant effects.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, France, Canada, Germany, Ireland, Switzerland
Thymoglobulin is a polyclonal antithymocyte globulin (ATG) product developed by Sanofi. It is a sterile, purified, and concentrated immunoglobulin preparation derived from the plasma of horses immunized with human thymocytes. Thymoglobulin is used as an immunosuppressant to prevent and treat acute rejection in organ transplantation.
Sourced in Switzerland
Myfortic is a mycophenolic acid-based immunosuppressant medication. It is used to prevent organ rejection in adult patients receiving kidney or heart transplants.
Sourced in Japan, United States, United Kingdom, Germany, Switzerland
Prograf is a laboratory equipment product manufactured by Astellas Pharma. It is used to measure and monitor the levels of the immunosuppressant drug tacrolimus in biological samples.
Sourced in United States, Japan, United Kingdom, Italy, Germany, Sao Tome and Principe, Denmark
Prednisolone is a synthetic corticosteroid used in the Merck Group's laboratory equipment. It functions as an anti-inflammatory and immunosuppressant agent.
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, Germany, United Kingdom, Switzerland, Japan, Macao, Italy
Cortisone is a laboratory equipment product manufactured by Merck Group. It is a corticosteroid compound used in various scientific and research applications.
Sourced in France, United States
Thymoglobuline is a polyclonal anti-thymocyte globulin (ATG) product derived from the serum of rabbits immunized with human thymocytes. It is used in the treatment of various medical conditions where immunosuppression is required, such as organ transplantation and some autoimmune disorders.

More about "Prednisone"

Prednisone is a synthetic glucocorticoid medication commonly used to treat a wide range of inflammatory and autoimmune conditions.
As a potent anti-inflammatory and immunosuppressive agent, prednisone is often prescribed for its ability to reduce swelling, redness, and other symptoms associated with these disorders.
Structurally similar to the naturally occurring hormone cortisol, prednisone can be administered orally, topically, or by injection, with healthcare providers closely monitoring its use due to the potential for adverse effects.
Researchers studying the efficacy and safety of prednisone products can utilize PubCompare.ai, an AI-driven platform that helps identify the most reproducible and effective prednisone formulations by comparing protocols from literature, preprints, and patents.
In addition to prednisone, other corticosteroid medications like prednisolone, dexamethasone, and cortisone are also commonly used to manage inflammatory and autoimmune conditions.
Immunosuppressant drugs such as Simulect, Thymoglobulin, Myfortic, and Prograf may also be prescribed in conjunction with prednisone to further modulate the immune system.
The use of dimethyl sulfoxide (DMSO) has also been investigated for its potential therapeutic effects in various medical applications.
By leveraging the insights and comparisons provided by PubCompare.ai, researchers can streamline their prednisone studies, optimize protocols, and ultimately improve patient outcomes.
This AI-driven platform helps identify the most reproducible and effective prednisone products, ensuring that research efforts are focused on the most promising avenues.